HC Wainwright Issues Positive Forecast for CG Oncology (NASDAQ:CGON) Stock Price

CG Oncology (NASDAQ:CGON – Get Free Report) had its price objective hoisted by HC Wainwright from $100.00 to $115.00 in a report released on Tuesday, Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright‘s price objective would suggest a potential upside of 35.65% from the company’s current price.

A number of other equities research analysts have also recently issued reports on the company. Royal Bank Of Canada cut CG Oncology from an “outperform” rating to a “sector perform” rating and boosted their price objective for the stock from $80.00 to $97.00 in a report on Tuesday. Truist Financial upped their target price on CG Oncology from $82.00 to $85.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Wall Street Zen upgraded CG Oncology from a “strong sell” rating to a “sell” rating in a research note on Saturday, November 7th. Piper Sandler lifted their price target on CG Oncology from $82.00 to $85.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of CG Oncology in a report on Thursday, October 15th. Eight equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $91.78.

View Our Latest Analysis on CG Oncology

CG Oncology Stock Performance

Shares of CGON stock opened at $84.78 on Tuesday. The company has a market capitalization of $7.57 billion, a price-to-earnings ratio of -30.72 and a beta of 0.35. The company has a 50-day simple moving average of $68.24 and a 200 day simple moving average of $66.70. CG Oncology has a 52 week low of $37.01 and a 52 week high of $93.95.

CG Oncology (NASDAQ:CGON – Get Free Report) last announced its quarterly earnings results on Friday, November 6th. The company reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.19. The business had revenue of $1.60 million for the quarter, compared to analyst estimates of $0.55 million. CG Oncology had a negative net margin of 3,851.09% and a negative return on equity of 24.58%. Sell-side analysts forecast that CG Oncology will post -3.00 EPS for the current year.

Insider Buying and Selling

In other news, Director Leonard E. Post sold 1,000 shares of the business’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $62.06, for a total value of $62,060.00. Following the completion of the transaction, the director directly owned 1,000 shares in the company, valued at approximately $62,060. The trade was a 50.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.80% of the stock is currently owned by corporate insiders.

Institutional Trading of CG Oncology

Several large investors have recently made changes to their positions in CGON. Aquatic Capital Management LLC increased its stake in CG Oncology by 111.2% in the third quarter. Aquatic Capital Management LLC now owns 24,435 shares of the company’s stock valued at $1,732,000 after acquiring an additional 12,867 shares during the last quarter. Goldman Sachs Group Inc. raised its position in CG Oncology by 32.5% during the third quarter. Goldman Sachs Group Inc. now owns 1,136,464 shares of the company’s stock valued at $80,564,000 after purchasing an additional 278,751 shares in the last quarter. Toronto Dominion Bank lifted its stake in CG Oncology by 177.7% during the third quarter. Toronto Dominion Bank now owns 798,676 shares of the company’s stock worth $56,618,000 after purchasing an additional 511,044 shares during the last quarter. Jump Financial LLC bought a new stake in CG Oncology during the third quarter worth $4,665,000. Finally, Marshall Wace LLP lifted its stake in CG Oncology by 179.8% during the third quarter. Marshall Wace LLP now owns 11,708 shares of the company’s stock worth $830,000 after purchasing an additional 7,523 shares during the last quarter. Institutional investors and hedge funds own 26.56% of the company’s stock.

CG Oncology News Summary

Investors following CGON have been watching these news items:

  • Positive Sentiment: In the PIVOT-006 trial, cretostimogene reduced the risk of bladder-cancer recurrence by 68% versus surveillance, meeting the primary endpoint with a hazard ratio of 0.32 (p<0.0001). The study enrolled 367 patients with intermediate-risk and high-grade Ta disease, a population of about 50,000 for which the company says there are no FDA-approved adjuvant treatments. Reuters article
  • Positive Sentiment: The treatment’s reported safety profile was favorable: no Grade 3 or higher treatment-related adverse events or treatment-related discontinuations. The results strengthen the case for cretostimogene as a potential treatment across a broader range of bladder-cancer patients. CG Oncology announcement
  • Positive Sentiment: CG Oncology expects to use PIVOT-006 data in a second biologics license application (BLA), targeted for Q2 2027. The company also plans to broaden its initial BLA for BCG-unresponsive disease to include high-grade papillary-only patients, with submission completion expected by March 2027.

About CG Oncology

(Get Free Report)

CG Oncology is a clinical-stage biotechnology company focused on developing treatments for bladder cancer. Based in Irvine, California, the company’s research centers on therapies delivered directly into the bladder. Its lead investigational therapy, cretostimogene grenadenorepvec (formerly CG0070), is an oncolytic immunotherapy being developed for non-muscle-invasive bladder cancer, including disease that has not responded to Bacillus Calmette-GuĂ©rin (BCG) treatment. The modified virus is designed to target cancer cells and stimulate an immune response.

Read More

Analyst Recommendations for CG Oncology (NASDAQ:CGON)

Receive News & Ratings for CG Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CG Oncology and related companies with MarketBeat.com's FREE daily email newsletter.